This was formally classified by the WHO in 2022 as a distinct entity, due to homogeneity within SF3B1‐mutated patients with erythroid dysplasia, ring sideroblasts, severe anemia, and a relatively good prognosis.19 The gene discussed is SF3B1; the disease is anemia.